ArticleFrontiers in immunology2026
Bioinformatics and machine learning approaches to explore the biomarkers in fatty acid degradation linked to osteoarthritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fatty acid degradation (FAD) plays a crucial role in maintaining cellular energy homeostasis, with its dysfunction serves as an important pathological basis for the progression of various diseases. However, the specific regulatory mechanisms of this process in osteoarthritis (OA) remain to be further elucidated. This study aims to identify potential FAD-associated biomarkers and to investigate the role and potential mechanisms of FAD in OA. Methods: OA-related datasets and FAD-associated genes were retrieved from publicly accessible databases. Multiple bioinformatics methods were employed to reveal the potential connections among the aforementioned genes. Screening FAD-associated differentially expressed genes highly correlated with OA (hub OA-FADEGs) using machine learning methods. Single-sample gene set enrichment analysis (ssGSEA) was employed to characterize immune cell infiltration in OA and to explore their correlations with FADEGs. Additionally, scatter plots were used to evaluate the diagnostic efficacy of hub OA-FADEGs. Finally, enrichment analysis of hub OA-FADEGs and their corresponding therapeutic drugs was performed using the Drug Signatures Database (DSigDB). Results: Machine learning algorithms were applied to screen for hub OA-FADEGs, identifying APOD, COL1A1, SULF1, CHI3L1, PENK, and ADM as genes that are significantly upregulated or downregulated in OA samples. These results were subsequently verified by qRT-PCR. Furthermore, the aforementioned genes all exhibit strong diagnostic efficacy for OA. Ultimately, we identified 28 therapeutic drugs that may target hub OA-FADEGs using DSigDB. Conclusion: Based on comprehensive bioinformatics analysis, this study proposes that 6 key hub OA-FADEGs, including APOD, COL1A1, SULF1, CHI3L1, PENK, and ADM, could serve as potential diagnostic biomarkers for OA and highlights their regulatory roles in disease progression. These findings provide novel insights into the metabolic pathogenesis underlying OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.